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http://www.translational-medicine.com/content/12/1/247RESEARCH Open AccessBioenergetic modulation with dichloroacetate
reduces the growth of melanoma cells and
potentiates their response to BRAFV600E inhibition
Cecilie Abildgaard1, Christina Dahl1, Astrid L Basse2, Tao Ma2 and Per Guldberg1*Abstract
Background: Advances in melanoma treatment through targeted inhibition of oncogenic BRAF are limited
owing to the development of acquired resistance. The involvement of BRAFV600E in metabolic reprogramming
of melanoma cells provides a rationale for co-targeting metabolism as a therapeutic approach.
Methods: We examined the effects of dichloroacetate (DCA), an inhibitor of pyruvate dehydrogenase kinase,
on the growth and metabolic activity of human melanoma cell lines. The combined effect of DCA and the BRAF
inhibitor vemurafenib was investigated in BRAFV600E -mutated melanoma cell lines. Vemurafenib-resistant cell lines
were established in vitro and their sensitivity to DCA was tested.
Results: DCA induced a reduction in glycolytic activity and intracellular ATP levels, and inhibited cellular growth.
Co-treatment of BRAFV600E-mutant melanoma cells with DCA and vemurafenib induced a greater reduction in
intracellular ATP levels and cellular growth than either compound alone. In addition, melanoma cells with in vitro
acquired resistance to vemurafenib retained their sensitivity to DCA.
Conclusions: These results suggest that DCA potentiates the effect of vemurafenib through a cooperative
attenuation of energy production. Furthermore, the demonstration of retained sensitivity to DCA in melanoma
cells with acquired resistance to vemurafenib could have implications for melanoma treatment.
Keywords: Dichloroacetate, Melanoma, BRAF, Bioenergetics, Metabolism, ATPBackground
A hallmark of cancer is the reprogramming of cellular
metabolism towards aerobic glycolysis. This metabolic
pattern is characterized by increased glucose uptake and
highly up-regulated glycolytic activity with fermentation
of glucose into lactic acid instead of complete aerobic
decomposition in the mitochondria. Aerobic glycolysis,
also referred to as the Warburg effect, resembles the an-
aerobic metabolism of normal cells, but occurs in the
context of an adequate oxygen supply [1]. The repro-
gramming of metabolism in cancer cells is a highly com-
plex and heterogeneous process, which is driven by a
wide variety of genetic and non-genetic strategies to
overcome energy restriction [2-4].* Correspondence: perg@cancer.dk
1Danish Cancer Society Research Center, Copenhagen, Denmark
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article, unless otherwise stated.The BRAFV600E oncogene, present in more than 50%
of melanomas [5], has been directly implicated in the re-
programming of cellular metabolism. The constitutive
activity of mutant BRAF reduces the expression of oxi-
dative enzymes and the number of mitochondria, while
increasing the expression of glycolytic enzymes and lactic
acid production [6,7]. Furthermore, a molecular link was
recognized between the RAS-RAF-MEK-ERK-MAPK
pathway and the energetic-stress check-point mediated by
the liver kinase B1 (LKB1)-AMP activated protein kinase
(AMPK) pathway, suggesting a role of BRAFV600E in me-
diating resistance to energetic stress [8,9]. BRAF affects
oxidative metabolism through microphthalmia-associated
transcription factor (MITF)-dependent control of the
mitochondrial master regulator PGC1α [7]. Previous stud-
ies have shown that melanomas expressing PGC1α have a
more oxidative phenotype than PGC1α-negative melano-
mas [4,7]. In addition, BRAFV600E was shown to mediatetral Ltd. This is an Open Access article distributed under the terms of the
/creativecommons.org/licenses/by/4.0), which permits unrestricted use,
, provided the original work is properly credited. The Creative Commons Public
mons.org/publicdomain/zero/1.0/) applies to the data made available in this
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tion. This mechanism involves an increase in pyruvate de-
hydrogenase (PDH) activity through the suppression of
pyruvate dehydrogenase kinase (PDK) [10]. PDH controls
the coupling between glycolysis and mitochondrial respir-
ation by facilitating the influx of pyruvate into the mito-
chondria, promoting complete utilization of glucose. The
PDK-PDH axis is often dysregulated in cancer, where PDK
over-expression reduces the coupling between the two en-
ergy systems and thereby contributes to the Warburg ef-
fect [11,12]. On the basis of these findings, targeted
inhibition of PDK was proposed as a therapeutic option
for melanoma, with a possible synergistic effect of chem-
ical BRAFV600E inhibitors, such as vemurafenib [10,13].
Dichloroacetate (DCA) is an inhibitor of the four iso-
forms of PDK and was previously used for treatment of
lactic acidosis [14,15], with low toxicity at effective dose
levels [16,17]. Several studies have demonstrated that
DCA reverses the Warburg effect in cancer cells and
negatively affects their growth and survival [13,18-21].
This effect was attributed to a normalization of the
mitochondrial membrane potential from the hyperpolar-
ized state that characterizes cancer cells. The changes in
membrane potential result in the reopening of voltage-
gated anion channels and were shown to introduce a
re-sensitization to apoptosis, due to a regained ability to
release pro-apoptotic mediators [18]. Here we have inves-
tigated the effect of DCA on melanoma cells. Specifically,
we analyzed cellular responses with regards to metabol-
ism, bioenergetics, growth, proliferation and cell death in
melanoma cell lines, primary human melanocytes, and




DCA (sodium dichloroacetate) and 2-Deoxy-D-glucose
(2-DG) were purchased from Sigma-Aldrich and dis-
solved in dH2O to working stock concentrations of 1 M.
Vemurafenib (PLX4032) was purchased from Selleck
Chemicals and dissolved in DMSO to a working stock
concentration of 0.05 M.
Cell culture
The melanoma cell lines ED-007, ED-013, ED-024, ED-
027, ED-029, ED-034, ED-050, ED-070, ED-071, ED-117,
ED-140, ED-179 and ED-196 were obtained from the
European Searchable Tumour line Database (ESTDAB,
ED) [22]. The melanoma cell line SK-MEL-28 was pur-
chased from ATCC. Primary human epidermal melano-
cytes (neonatal) from lightly pigmented tissue (HEMn-LP)
were purchased from Invitrogen. The melanoma cell lines
were cultured at 37°C under 5% CO2 in RPMI-1640
medium supplemented with 10% fetal bovine serum and1% penicillin/streptomycin. HEMn-LP cells were cultured
under the same conditions in 254CF medium supple-
mented with 1% human melanocyte growth supplement
(HMGS-2) and 12-O-tetradecanoyl-phorbol-13-acetate
(TPA; 10 ng/ml). All media and supplements were pur-
chased from Invitrogen.
Metabolic analysis
Metabolic characterization was performed on melanoma
cell lines and primary human melanocytes using a Seahorse
XF96 extracellular flux analyzer (Seahorse Bioscience,
Billerica, MA), which performs real-time measurements
of extracellular acidification rate (ECAR) and oxygen
consumption rate (OCR). An assay was designed to
study the capacity of the mitochondrial and glycolytic
energy systems. The ECAR and OCR were measured
under basal conditions and during successive addition
of five metabolic modulators: The ATP synthase inhibi-
tor, oligomycin (1 μM); the mitochondrial membrane
permeabilizer, carbonyl cyanide-4-(trifluoromethoxy)
phenylhydrazone (FCCP) (1 μM); the inhibitors of mito-
chondrial respiration, rotenone (1 μM) and antimycin A
(1 μM); and the glycolytic inhibitor, 2-DG (100 mM).
The XF Cell Mito Stress Kit, containing oligomycin,
FCCP, rotenone and antimycin A, was purchased from
Seahorse Bioscience.
ATP measurements
Intracellular ATP levels were measured using the ATPlite,
1 step Luminescence Assay System (Perkin Elmer), a
method based on the reaction of ATP with luciferase
and D-luciferin. The cells were seeded in triplicates with
10,000 cells per well and treated with the indicated
compounds and vehicle control for 2 or 24 hours. Lumi-
nescence was measured with Spectra Max Gemini EM
luminescence microplate reader (Molecular Devices)
and normalized to background levels.
Crystal violet assay
A crystal violet assay was applied to evaluate the effect
of the studied compounds on cell growth. Cells were
seeded in duplicates at a suitable density and then treated
with DCA, vemurafenib, the two compounds combined
and vehicle control. Medium and the treatment com-
pounds were replaced every 48 hours. The experiment
was repeated three times independently. To terminate the
experiment, medium and unattached cells were removed,
and the remaining cells were washed in PBS and fixed
with glutaraldehyde for 15 minutes. The fixed cells were
incubated with crystal violet solution (0.1% crystal violet,
20% CH3OH) for 1 hour. The amount of dye taken up by
the monolayer, proportional to the number of viable cells
attached to the well bottom, was quantified by extracting
the color with 10% acetic acid and measuring the
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ation between the absorbance and the number of cells was
verified by performing a standard curve. Relative cell
growth was determined by normalizing to the untreated
controls after background (without cells) subtraction.
Cell proliferation assay
Melanoma cells were seeded in triplicates with 500–
1,000 cells per well and treated with DCA at the given
concentrations and vehicle control for 96 hours. Prolifer-
ation was then measured by detecting BrdU after
12 hours of incorporation into cellular DNA. The pro-
cedure was conducted according to the protocol pro-
vided with the BrdU Cell Proliferation Assay Kit (Cell
Signaling Technology®).
Annexin V-FITC apoptosis detection
Apoptosis detection was performed using an Annexin
V-FITC apoptosis detection kit (BD Bioscience), accord-
ing to the provided protocol. Cells were harvested and
washed twice in cold PBS. The cells were then trans-
ferred to another tube, spun down and resuspended in
binding buffer. From the resuspension, 5 × 105 cells were
transferred to FACS tubes and stained with Annexin V-
FITC and propidium iodide (PI). After 30 minutes incu-
bation, flow cytometry was performed on a Cytomics FC
500 MPL instrument (Beckman Coulter). Unstained cells
were included as control.
Induction of in vitro acquired vemurafenib resistance
Acquired resistance to vemurafenib was induced in
seven cultures derived from four BRAFV600E-mutant,
vemurafenib-sensitive melanoma cell lines (ED-013, ED-
071, ED-196 and SK-MEL-28). Cells were cultured in in-
creasing concentrations of vemurafenib until they grew
steadily in a concentration above the IC50, and were then
maintained in medium containing vemurafenib.
Pyrosequencing
Pyrosequencing of mutation hotspots in BRAF and
NRAS was performed on a PyroMark Q24 platform
(Qiagen), using PyroMark Gold Q24 Reagents (Qiagen).
The primer sequences are listed in Additional file 1:
Table S1.
PGC1α expression analysis
Total RNA was isolated using RNeasy mini kit (Qiagen)
and cDNA was synthesized with the SuperScript™ III
Reverse Transcriptase kit (Invitrogen). Oligo dT24 and
random hexamers were used as primers for cDNA
synthesis. Gene expression of PGC1α was determined
with quantitative real-time PCR on Roche LightCycler
2.0 using LigthCycler FastStart DNA MasterPLUS SYBR
Green I kit (Roche). The primer sequences were:PPARGC1A_2241F: 5′-GCTGTACTTTTGTGGACGC
A-3′ and PPARGC1A_2306R: 5′-GGAAGCAGGGT-
CAAAGTCAT-3′. The expression was normalized to
the expression of the housekeeping gene RPLP0. The
primer sequences were: RPLP0_433F: 5′-ACTAAAATC
TCCAGGGGCACC-3′ and RPLP0_547R: 5′-ATGAC-
CAGCCCAAAGGAGAA-3′. The two melanoma cell
lines ED-050 and SK-MEL-28 were included as positive
and negative controls, respectively [4].
Statistical analysis
Differences between independent data sets were deter-
mined with Student’s t-test. One-way matched-samples
ANOVA was used for statistical analysis of variance be-
tween different treatments (vehicle control, DCA,
vemurafenib and the combination of DCA and vemura-
fenib). Tukey’s honest significance difference (HSD)
multi-comparison test was used to determine statistical
significance. Pearson’s correlation coefficient was used
to determine correlation between DCA sensitivity and
metabolic parameters. A value of 1 indicated a positive cor-
relation, 0 no correlation, and −1 a negative correlation.
The experiments performed in this study involved only
commercially available cell lines and therefore required
no ethics committee approval.
Results
Metabolic characterization of melanoma cell lines and
primary melanocytes
Metabolic profiling of 12 melanoma cell lines and pri-
mary human melanocytes (HEMn-LP) was performed
using the Seahorse FX96 analyzer. This instrument per-
forms real-time measurements of the extracellular acid-
ification rate (ECAR) and the oxygen consumption rate
(OCR), which are indirect measures of glycolytic activity
and mitochondrial respiration, respectively [23]. The
measurements were performed under basal conditions
and during the successive addition of five metabolic
modulators (Figure 1A). Compared with normal melano-
cytes, 11 out of 12 cell lines presented with higher glyco-
lytic rates, as indicated by higher basal glycolytic ECARs,
showing that the Warburg effect is a general characteris-
tic of melanoma cells. Furthermore, nine of the cell lines
exhibited higher maximal glycolytic capacities compared
with melanocytes (Figure 1B). With few exceptions, there
were no significant differences in basal and maximal mito-
chondrial respiration between melanocytes and melanoma
cells (Additional file 2: Figure S2). According to the OCR-
to-ECAR ratios (OCR/ECAR; Figure 1C), the relative
contribution from mitochondrial respiration to ATP
production was lower in 10 of the melanoma cell lines
compared with melanocytes.
Mitochondrial efficiency (ATP coupling) and perform-
ance (respiratory control ratio) were estimated from
Figure 1 (See legend on next page.)
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Figure 1 Metabolic characterization of melanoma cell lines and primary melanocytes. A, Metabolic profiles of two melanoma cell lines
(ED-013 and ED-179) and human epidermal melanocytes (HEMn-LP), based on Seahorse XF96 measurements. Depicted are the ECAR (left panel)
and the OCR (right panel) measurements during successive addition of oligomycin (1 μM), FCCP (1 μM), rotenone/antimycin (1 μM/1 μM) and
2-DG (100 mM). Data constitute 6 parallel measurements, and are representative of three independent experiments. B, Basal and maximal
glycolytic ECAR values for melanoma cell lines and human primary melanocytes (HEMn-LP). The ECAR measured after addition of 2-DG
(non-glycolytic ECAR) was subtracted from all values. The dashed line indicates the basal ECAR of HEMn-LP. C, Ratios between basal mitochondrial
OCR and basal glycolytic ECAR. D, ATP coupling representing the fraction of the basal OCR used for ATP production (fraction inhibited by
oligomycin). E, The respiratory control ratio, denoting the ratio between the maximal mitochondrial OCR and the proton leak (OCR after addition
of oligomycin). (B – E), Values are the means of three independent measurements ± standard deviation. Students t-test was used to determine
differences between HEMn-LP and melanoma cell lines (*p < 0.05; **p < 0.01; ***p < 0.001).
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function; proton leak and the maximal mitochondrial
OCR [24]. The proton leak was determined after the
addition of the ATP synthase inhibitor oligomycin, and
the maximal mitochondrial OCR was determined after
the addition of the mitochondrial uncoupler FCCP. This
analysis showed a significantly lower ATP coupling in
melanoma cells compared with melanocytes (p < 0.05;
ED-007: p = 0.07), suggesting a higher proton leak and a
less efficient production of ATP relative to the level of
oxygen consumption (Figure 1D). Furthermore, six of
the melanoma cell lines also had significantly lower respira-
tory control ratios than melanocytes (p < 0.01, Figure 1E),
indicative of a poor mitochondrial performance.
DCA shifts the metabolism towards mitochondrial
respiration and reduces ATP levels
To determine the effect of DCA on melanoma cell me-
tabolism, we analyzed the panel of 12 cell lines using the
Seahorse XF96 analyzer. After treatment with 10 mM
DCA for 2 hours, all cell lines responded with a reduc-
tion in ECAR and an increase in OCR (Figure 2A), indi-
cating a shift towards mitochondrial respiration. TheFigure 2 Effects of DCA on metabolism and ATP levels. A, Relative cha
treatment with 10 mM DCA for 2 hours. B, Relative ATP levels after treatme
ANOVA was used for statistical analysis and Tukey’s HSD test was used to dECAR response was similar among the cell lines,
whereas there was a large variation in the OCR response
(Figure 2A). The relative changes in ECAR, OCR and
OCR/ECAR in response to DCA were concentration
dependent (Additional file 3: Figure S3).
To determine if the shift in metabolism interfered with
energetic homeostasis, we measured ATP levels in mel-
anoma cells after treatment with 0.1, 1 or 10 mM DCA
for 2 hours. All three cell lines tested were able to sus-
tain ATP levels after treatment with low concentrations
of DCA (0.1-1 mM), whereas a trend towards reduced
ATP was observed in cultures treated with 10 mM DCA
(Additional file 3: Figure S3). When cells were treated
with DCA (10 or 20 mM) for 24 hours, a significant
concentration-dependent decrease in ATP was observed
(Figure 2B), indicating a gradual exhaustion of the meta-
bolic system.
DCA reduces the growth of melanoma cells independent
of genetic-driver and PGC1α-expression status
To assess a possible clinical application of DCA for
treatment of melanoma, we studied its effects on differ-
ent parameters for cellular growth. The entire panel ofnges in basal mitochondrial OCR and glycolytic ECAR induced by
nt with DCA (10 or 20 mM) for 24 hours. One-way matched-samples
etermine statistical significance (*p < 0.05; **p < 0.01).
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range of DCA concentrations (0.5-100 mM) for 96 hours
(see Figure 3A for representative results). All cell lines
showed a concentration-dependent reduction in growth,
with IC50 values in the range of 9–38 mM (Table 1),
compared with an IC50 value of 70 mM for primary me-
lanocytes (p < 0.001). There was no correlation between
the response to DCA and either the BRAF/NRAS muta-
tion status or the expression levels of PGC1α (Table 1).
To further characterize the effects of DCA on cellular
growth, we measured the incorporation of BrdU in cells
treated with 1 or 10 mM DCA for 96 hours. As shown
in Figure 3B, all four cell lines tested responded with re-
duced proliferation, in the range of 11-30% at 1 mM and
of 42-88% at 10 mM. We also measured the apoptotic
response to DCA by flow-cytometric analysis of annexin
V levels. At concentrations of DCA below IC50, theFigure 3 Effects of DCA on growth, proliferation and apoptosis. A, Re
(ED-007, ED-070, ED-179 and ED-196) treated with increasing concentration
incorporation of BrdU after treatment with DCA (1 and 10 mM) for 96 hou
and Tukey’s HSD test was used to determine statistical significance (*p < 0.
apoptosis in ED-179 and ED-196 cells after treatment with DCA at concentnumber of annexin V-positive cells did not increase after
96 hours and up to 3 weeks. In contrast, treatment with
concentrations above the IC50 increased the number of
cells positive for both annexin V and PI, indicating in-
duction of cell death already after 96 hours (Figure 3C).
DCA potentiates the effect of vemurafenib on BRAFV600E-
mutant melanoma cells
To investigate if DCA can be used to improve the effi-
ciency of chemical BRAF inhibitors for treatment of
melanoma, we tested various combinations of DCA and
vemurafenib on cellular growth. Treatment of four
BRAFV600E-mutant cell lines with vemurafenib (0.05-
5 μM) for 96 hours revealed IC50 values from 0.5 to
4.5 μM, consistent with data from previous studies [26].
When exposing primary melanocytes to the same treat-
ment, we did not reach the IC50 value for these cells, evenpresentative selection of crystal violet stains of four melanoma cell lines
s of DCA (1–50 mM) for 96 hours. B, Proliferation determined by the
rs. One-way matched-samples ANOVA was used for statistical analysis
05; **p < 0.01). C, Annexin V and PI based flow cytometric detection of
rations below (10 mM) and above (100 mM) the IC50 for 96 hours.
Table 1 DCA IC50 values, BRAF/NRAS status and PGC1α expression
Cell line DCA IC50 (mM)
4 BRAF/NRAS Status1 PGC1α expression2,4
ED-070 8.9 ± 0.6*** NRASQ61L 1.0 ± 0.2
ED-007 12.2 ± 2.2*** WT3 0.6 ± 0.0
ED-071 12.3 ± 3.6*** BRAFV600E 0.0 ± 0.0
ED-034 12.7 ± 1.7*** BRAFL597S 1.0 ± 0.2
ED-013 14.4 ± 2.0*** BRAFV600E 1.9 ± 0.3
ED-027 17.7 ± 2.1*** BRAFV600E 0.5 ± 0.1
SK-MEL-28 20.0 ± 4.5*** BRAFV600E 0.0 ± 0.0
ED-179 20.6 ± 1.8*** NRASQ61R 0.3 ± 0.0
ED-024 21.9 ± 1.6*** NRASQ61L 0.0 ± 0.0
ED-140 23.9 ± 2.0*** WT 0.4 ± 0.1
ED-050 24.1 ± 3.1*** WT 2.7 ± 0.5
ED-029 29.7 ± 5.1*** BRAFV600K 1.3 ± 0.2
ED-196 35.8 ± 3.2*** BRAFV600E 1.5 ± 0.5
ED-117 37.6 ± 2.2*** BRAFV600E 1.2 ± 0.1
HEMn-LP 69.1 ± 6.4 WT 1
ED-013-R1 12.6 ± 3.0*** BRAFV600E
ED-013-R2 13.6 ± 2.4*** BRAFV600E
ED-071-R1 12.2 ± 0.9*** BRAFV600E
ED-071-R2 13.8 ± 3.7*** BRAFV600E
SK-MEL-28-R1 23.1 ± 4.6*** BRAFV600E
SK-MEL-28-R2 26.2 ± 8.0** BRAFV600E
**p < 0.01; ***p < 0.001 when compared with HEMn-LP.
1BRAF/NRAS status are in accordance with published results [25].
2Relative to PGC1α expression in normal melanocytes.
3wild type.
4DCA IC50 values and PGC1α expression represent the means of three independent measurements ± standard deviation.
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the specificity of the compound.
When cells were treated with 1 mM DCA in combin-
ation with low concentrations of vemurafenib (<IC50), the
reduction in cellular growth was more pronounced than
with DCA or vemurafenib alone (p < 0.05; Figure 4A, B).
DCA did not potentiate the effect of vemurafenib in ED-
117 cells, which may be attributed to the inherent resist-
ance of these cells to DCA (IC50 38 mM; Table 1). At IC50
concentrations, both DCA and vemurafenib caused a
reduction in intracellular ATP levels when used as sin-
gle agents and a further reduction when used in com-
bination, although not statistically significant for all cell
lines (Figure 4C).
Vemurafenib-resistant cell lines have improved oxidative
capacity and retain sensitivity to DCA
Seven cultures of vemurafenib-resistant cells were gener-
ated from four BRAFV600E-mutant cell lines by exposing
the cells to increasing concentrations of vemurafenib.
Cells were considered resistant when they could con-
tinuously be propagated at a concentration of vemurafe-
nib above the IC50. DNA was isolated from all sevencultures and tested for BRAF copy number gain and sec-
ondary NRAS mutations, which are two well-described
mechanisms of acquired resistance to vemurafenib [27,28].
Pyrosequencing revealed an increase in the ratio of
BRAFV600E to BRAFWT in one of the resistant cell
lines (ED-013-R2) compared with the parental cell
line (Additional file 4: Figure S4). No BRAF or NRAS al-
terations were found in the remaining resistant cell lines.
Metabolic characterization of two of the resistant cell
lines (ED-013-R1 and ED-196-R) using the Seahorse
XF96 analyzer showed that both resistant cell lines had a
transformed metabolic profile with a significantly in-
creased maximal respiratory capacity (Figure 5A), but no
changes in basal respiratory OCR, ATP coupling or non-
mitochondrial OCR. Interestingly, when tested for sensi-
tivity to DCA, the vemurafenib-resistant cell lines all
had IC50 values similar to those for the parental cell lines
(Table 1).
Figure 5B illustrates the sensitivity of vemurafenib-
resistant cell lines to DCA and vemurafenib, as single
agents or in combination, compared with the parental cell
lines. The growth of the resistant cell lines was slightly de-
creased, unaffected or even increased in the presence of
Figure 4 (See legend on next page.)
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Figure 4 Effects of combined treatment with DCA and vemurafenib. A, B, Four melanoma cell lines (ED-013, ED-071, ED-117 and ED-196)
were treated with DCA (1 mM), vemurafenib (50 nM for ED-071 and ED-117; 100 nM for ED-013 and ED-196) or the combination for 2 weeks. A,
Crystal violet staining results representative of three independent experiments. B, Quantification of the data exemplified in A. C, Relative ATP levels
in cells treated with DCA (IC50), vemurafenib (IC50) or the combination for 24 hours. B, C, Data represent means ± standard deviation of three
independent measurements. One-way matched-samples ANOVA was used for statistical analysis and Tukey’s HSD test was used to determine
statistical significance (*p < 0.05; **p < 0.01).
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DCA was similar to the parental cells, both in the pres-
ence and absence of vemurafenib (Figure 5B). Similar
results were obtained when measuring changes in ATP
levels after treatment with the same drugs for 24 hours
(Figure 5C). All together, these data show that the
vemurafenib-resistant melanoma cells retained sensitivity
to DCA, despite the change in their metabolic profile.
Discussion
Metabolic targeted therapy for cancer has been primarily
focused on targeting the energy supply through inhibition
of glycolysis. However, the recognition that mitochondria
may be active contributors to melanoma progression has
increased the attention on oxidative metabolism as a po-
tential therapeutic target [10,13,29]. DCA promotes PDK-
dependent activation of PDH, reversing lactate production
in favor of influx of pyruvate into the mitochondria
[15,18]. Through this mechanism, DCA improves the
coupling between glycolysis and mitochondrial respir-
ation, which will have a greater impact on cells with a defi-
cient coupling, such as cancer cells [18]. All melanoma
cell lines examined in our study responded to DCA with
reduced lactate production and an increased OCR. This
shift towards mitochondrial respiration was expected to
optimize substrate utilization and lead to a more efficient
energy yield, but instead led to a significant drop in ATP
levels despite an unaffected or even increased mitochon-
drial ATP coupling. The observed reduction in ECAR in
response to DCA suggests that inhibition of glycolysis
could be a major contributor to energy deprivation. A
glycolysis-inhibitory mechanism of DCA has not been
previously described. However, it has been demonstrated
that pyruvate kinase, the last ATP-producing site in the
glycolytic pathway, is negatively regulated by acetyl co-
enzyme A (acetyl-CoA) [30]. As PDH activation directly
increases the formation of acetyl-CoA [31], this could
explain the DCA-mediated inhibition of glycolysis. The
structural similarity between DCA and pyruvate [32]
could also imply a direct inhibition of glycolysis by DCA,
possibly through an allosteric feedback mechanism.
The metabolic response to DCA was accompanied by
reduced proliferation of melanoma cells, independent of
the genetic driver status and metabolic profiles of these
cells. Several previous studies have demonstrated an
apoptotic effect of DCA on cancer cells [13,18,19,32-34].However, in accordance with our results, the apoptotic
response was only triggered at concentrations too high
to be clinically relevant [32]. To further explore the clinical
relevance of DCA to melanoma treatment, we examined
the efficacy of this agent in combination with the BRAF in-
hibitor vemurafenib. These experiments demonstrated a
potentiating effect of DCA on the growth inhibition of
BRAFV600E-mutant melanoma cells. At low concentrations
of DCA that alone had no effect on cell growth, the
combination with low concentrations of vemurafenib
had a significantly stronger growth-reducing effect than
vemurafenib alone. This potentiating effect of DCA was
also reflected in the reduction of ATP levels. Biochem-
ical analysis has demonstrated the ability of BRAFV600E
to uncouple the LKB1-AMPK energy sensing pathway,
promoting resistance to energy deprivation and prevent-
ing an apoptotic response [8,9]. Treatment with BRAF
inhibitors restores this pathway [35] and may, therefore,
potentiate the response to compounds that reduce the
generation of ATP. Both DCA and vemurafenib sup-
press glycolytic activity in melanoma cells and thus ren-
der them more dependent on mitochondrial respiration
[6]. As glycolysis accounts for a large fraction of the
total energy production in these cells, inhibition of this
process will place a high demand on the oxidative sys-
tem for ATP production. The lower performance of the
mitochondria in melanoma cells could explain the in-
ability of these cells to sustain ATP levels in the pres-
ence of DCA and vemurafenib. The cooperative effect
of these compounds in lowering ATP levels suggests
that the energetic threshold promoting growth arrest or
cell death in melanoma cells can be reached with lower
concentrations of vemurafenib in the presence of DCA.
Previous studies have investigated the ability of meta-
bolic modulators to improve the therapeutic effect of
BRAF inhibitors for treatment of melanoma. The com-
bination of PLX4720 (a vemurafenib analogue) with ei-
ther of the two anti-diabetic biguanides, metformin and
phenformin, showed synergistic inhibition of melanoma
cell viability [35,36]. Both agents impair ATP synthesis
through inhibition of the mitochondrial complex I activ-
ity, leading to a reduction in the ATP to ADP ratio and
activation of the LKB1-AMPK pathway to suppress
growth [35,36]. Unlike DCA, metformin and phenformin
both stimulate glycolysis and lactic acid production
[37,38], which could explain the growth-stimulating
Figure 5 Response of vemurafenib-resistant melanoma cell lines to DCA. A, Metabolic profiles of two vemurafenib-resistant melanoma cell
lines (ED-013-R1 and ED-196-R) compared with their parental cell lines (ED-013 and ED-196). The panels indicate the basal OCR and the changes
during successive addition of oligomycin (1 μM), FCCP (1 μM), rotenone/antimycin (1 μM/1 μM) and 2-DG (100 mM). Data constitute 6 parallel
measurements and are representative of three independent experiments. B, Relative cell growth of vemurafenib sensitive cell lines (ED-013,
ED-071 and SK-MEL-28) and their vemurafenib resistant sub-cultures (denoted R1 and R2) after treatment with DCA (10 mM), vemurafenib (1 μM)
or the combination for 96 hours. C, Relative ATP levels after treatment with DCA (IC50), vemurafenib (IC50) or the combination for 24 hours.
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used as a single agent. In addition, the concentrations at
which metformin was effective were above a therapeuticallyrelevant level [35]. Phenformin was significantly more po-
tent than metformin [36], but has been associated with a
high risk of lactic acidosis [39], and was taken off the
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http://www.translational-medicine.com/content/12/1/247market for treatment of type 2 diabetes in many coun-
tries. DCA, on the other hand, was here demonstrated
to potentiate the effect of vemurafenib at concentrations
down to 1 mM, and was previously shown to have few
adverse effects when administered to patients [17,19,40].
These findings allude to a therapeutic potential of DCA as
a co-drug for vemurafenib treatment of BRAFV600E-mu-
tant melanoma. This was reinforced by the demonstration
that sensitivity to DCA was retained in melanoma cell
lines with acquired resistance to vemurafenib. Although
resistant cells showed an altered metabolic profile with
significantly increased maximal mitochondrial respiration,
as also shown by Corazao-Rozas et al. [41], they were as
sensitive to DCA as the parental vemurafenib-sensitive
cells. Therefore, DCA could possibly provide a strategy to
prevent the appearance of vemurafenib-tolerant subpopu-
lations during initial treatment and thereby postpone or
prevent the development of resistance.Conclusions
We here provide a more elaborate understanding of the
effects of DCA on the metabolism and growth of melan-
oma cells. The ability of DCA to lower ATP levels and
melanoma growth appears to potentiate the effect of
vemurafenib, a drug already used in the clinic for treat-
ment of BRAFV600E-mutant metastatic melanomas. Im-
portantly, melanoma cells with acquired resistance to
vemurafenib retained their sensitivity to DCA. These
findings should encourage further investigation of this
drug combination and the in vivo application of DCA.Additional files
Additional file 1: Table S1. Pyrosequencing primers for amplification
and sequencing of BRAF and NRAS mutation hotspots. Forward, reverse
and sequencing primers are denoted F, R and S, respectively.
Additional file 2: Figure S2. Basal and maximal mitochondrial OCR
values for melanoma cell lines and human epidermal melanocytes
(HEMn-LP). The OCR measured after addition of rotenone/antimycin A
(non-mitochondrial OCR) was subtracted from all values. The dashed line
indicates the basal OCR of HEMn-LP. The indicated values are means of
three independent measurements ± standard deviation. Students t-test
was used to determine differences between HEMn-LP and the melanoma
cell lines (*p < 0.05; **p < 0.01; ***p < 0.001). The maximal mitochondrial
OCR for ED-034 was not indicated due to a very large variation among
four independent experiments, ranging from 6.19 to 58.36 pmoles/min/
1,000 cells.
Additional file 3: Figure S3. Metabolic response of melanoma cells to
DCA Relative response in ECAR, OCR, OCR/ECAR and ATP levels after
treatment with DCA (0.1, 1 and 10 mM) for 2 h. The error bars in the first
three panels represent standard deviations of three repeated measurements
of six parallel samples. The error bars in the lower panel represent the
standard deviation of three independent experiments. One-way matched-
samples ANOVA was used for statistical analysis and Tukey’s HSD test was
used to determine statistical significance (*p < 0.05; **p < 0.01).
Additional file 4: Figure S4. Allele status of BRAF. Pyrosequencing of
the BRAF c.1799 T > A mutation site in ED-013 and the vemurafenib
resistant derivative ED-013-R2. The increased BRAFV600E-to-BRAFWT ratio inED-013-R2 indicates a copy number gain, which could explain the
resistance to vemurafenib.
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